EANS-Adhoc: Intercell AG / Intercell starts clinical trial in Pandemic Influenza with its Vaccine Enhancement Patch and provides update to the strategic collaboration with GSK on patches

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

Research & Development

04.05.2011

» Intercell starts a confirmatory clinical study using the Vaccine
Enhancement Patch in combination with GSK's H5N1 pandemic
Influenza antigen » GSK and Intercell underline their commitment to
advancing the value of the patch technology in the research &
development of patch delivered vaccines.

Vienna (Austria), May 04, 2011 - Today Intercell AG (VSE: ICLL)
announced the start of a further trial in the field of pandemic
Influenza, investigating Intercell's adjuvant patch (Vaccine
Enhancement Patch - VEP) containing LT (a heat-labile toxin from E.
coli) in combination with GSK's H5N1 pandemic antigen. This trial
follows prior work with a non-GSK pandemic Influenza antigen carried
out by Intercell under its contract with the U.S. Department of
Health and Human Services (HHS) to develop a dose-sparing approach
with potential for a single dose immunization.

The confirmatory trial will be performed under a Phase I protocol due
to the introduction of a different H5N1 antigen. The study will
involve 300 healthy adults and investigate various combinations of
antigen and patch doses in one and two injection regimes to confirm
mode of action and the value of "external" adjuvantation. GSK's
adjuvanted and licensed H5N1 vaccine will be used to provide a
positive control for the patch and GSK's well established and
validated H5N1 hemagglutination inhibition (HI) assay will be
applied.

Intercell and GSK have maintained their commitment to continue to
explore the value of the patch technology and will focus on
evaluating the use of the patch technology for transcutaneous
vaccination with existing or new antigens. Following the
discontinuation of the Travelers' Diarrhea (TD) patch vaccine program
as announced at the end of 2010, Intercell and GSK have mutually
terminated the respective marketing and distribution collaboration.
On this basis, all rights on the TD patch vaccine revert back to
Intercell. Based on the clinical efficacy data obtained against
LT-positive enterotoxigenic E. coli (ETEC) the company will continue
to evaluate the potential of the vaccine candidate especially for
endemic countries.

"We are pleased to continue our partnership with GSK to accelerate
the development of needle?free, patch?based vaccines. We are also
looking forward to investigating further the potential of our
Vaccines Enhancement Patch (VEP) with this confirmatory clinical
study in our pandemic Influenza program," stated Thomas Lingelbach,
Chief Operating Officer of Intercell.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222
communications@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market